Drug class
Ophthalmic anti-cataract agent; quinone-opacification inhibitor
Mechanism of action
Competes with quinone compounds implicated in oxidation and insolubilisation of water-soluble lens proteins. It is intended to maintain lens protein solubility and retard progression of early lens opacity; evidence of clinical benefit is limited and product use is jurisdiction-specific.
General use cases
- Topical ophthalmic treatment intended to retard progression of early senile cataract in Japan and selected Asian markets; this is not a treatment for advanced cataract or a substitute for surgery.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
